Get the Stockscreener App
1.35
3.94%
0.05
Allogene Therapeutics Inc stock is traded at $1.35, with a volume of 699.53K.
It is up +3.94% in the last 24 hours and up +21.73% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.30
Open:
$1.29
24h Volume:
699.53K
Relative Volume:
0.22
Market Cap:
$319.35M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.6368
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-6.81%
1M Performance:
+21.73%
6M Performance:
-29.07%
1Y Performance:
-39.41%
1-Day Range:
$1.26
$1.36
1-Week Range:
$1.26
$1.45
52-Week Range:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.35 | 319.35M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.63 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
514.76 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.49 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.97 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
256.01 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data By Investing.com - Investing.com India
Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com
Allogene's SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Insider Sell: Deborah Messemer Sells 36,885 Shares of Allogene T - GuruFocus
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Yahoo Finance
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now - simplywall.st
Allogene Therapeutics at Jefferies Conference: Delays and Optimism By Investing.com - Investing.com Canada
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Yahoo Finance
Allogene Therapeutic's ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma - CRISPR Medicine News
Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma - MSN
Citi maintains buy rating on Allogene stock following ASCO data - Investing.com Australia
Citi maintains buy rating on Allogene stock following ASCO data By Investing.com - Investing.com India
Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - The Manila Times
Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025 - Nasdaq
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO - marketscreener.com
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Canada
Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail
Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia
Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times
Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus
ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):